A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation
study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when
given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis
(CIMF) regardless of their JAK2 mutational status. The second portion of the study is a Phase
2 study to define the efficacy and safety profile of single agent SB1518 at the recommended
dose in subjects with CIMF.